Membrane-interactive Lipids As Experimental Anticancer Drugs

Overview

Journal Br J Cancer

Specialty Oncology

Date 1991 Aug 1

PMID 1892746

Citations 17

Authors

W E Berdel

Affiliations

Soon will be listed here.

Citing Articles

Impact of targeting the platelet-activating factor and its receptor in cancer treatment.

Qaderi K, Shahmoradi A, Thyagarajan A, Sahu R Mil Med Res. 2025; 12(1):10.

PMID: 40033370 PMC: 11877967. DOI: 10.1186/s40779-025-00597-0.

Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe.

Berdel W Cancers (Basel). 2022; 14(5).

PMID: 35267614 PMC: 8909270. DOI: 10.3390/cancers14051308.

Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells.

Ansari S, Sharma A, Zepp M, Ivanova E, Bergmann F, Konig R Oncotarget. 2018; 9(5):5797-5810.

PMID: 29464035 PMC: 5814175. DOI: 10.18632/oncotarget.23537.

Evaluation of in vitro and in vivo anti-inflammatory activity of biologically active phospholipids with anti-neoplastic potential in porcine model.

Vicenova M, Nechvatalova K, Chlebova K, Kucerova Z, Leva L, Stepanova H BMC Complement Altern Med. 2014; 14:339.

PMID: 25234616 PMC: 4179840. DOI: 10.1186/1472-6882-14-339.

Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.

Perez-Victoria F, Castanys S, Gamarro F Antimicrob Agents Chemother. 2003; 47(8):2397-403.

PMID: 12878496 PMC: 166066. DOI: 10.1128/AAC.47.8.2397-2403.2003.

References

Kucera L, Iyer N, LEAKE E, Raben A, MODEST E, Daniel L . Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation. AIDS Res Hum Retroviruses. 1990; 6(4):491-501. DOI: 10.1089/aid.1990.6.491. View

Runge M, Andreesen R, Pfleiderer A, MUNDER P . Destruction of human solid tumors by alkyl lysophospholipids. J Natl Cancer Inst. 1980; 64(6):1301-6. DOI: 10.1093/jnci/64.6.1301. View

Seewald M, Olsen R, Sehgal I, Melder D, MODEST E, Powis G . Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues. Cancer Res. 1990; 50(15):4458-63. View

Verdonck L, Witteveen E, van Heugten H, Rozemuller E, Rijksen G . Selective killing of malignant cells from leukemic patients by alkyl-lysophospholipid. Cancer Res. 1990; 50(13):4020-5. View

Lazenby C, Thompson M, Hickman J . Elevation of leukemic cell intracellular calcium by the ether lipid SRI 62-834. Cancer Res. 1990; 50(11):3327-30. View

Kosano H, Yasutomo Y, Kugai N, Nagata N, Inagaki H, Tanaka S . Inhibition of estradiol uptake and transforming growth factor alpha secretion in human breast cancer cell line MCF-7 by an alkyl-lysophospholipid. Cancer Res. 1990; 50(11):3172-5. View

Berdel W, Bausert W, Weltzien H, Modolell M, Widmann K, MUNDER P . The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur J Cancer (1965). 1980; 16(9):1199-204. DOI: 10.1016/0014-2964(80)90179-6. View

BAZILL G, Dexter T . Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells. Cancer Res. 1990; 50(23):7505-12. View

Kosano H, Takatani O . Increase of transferrin binding induced by an alkyl-lysophospholipid in breast cancer cells. J Lipid Mediat. 1990; 2(2):117-21. View

10.

Andreesen R, Modolell M, Weltzien H, Eibl H, Common H, LOHR G . Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res. 1978; 38(11 Pt 1):3894-9. View

11.

Berdel W . Ether lipids and derivatives as investigational anticancer drugs. A brief review. Onkologie. 1990; 13(4):245-50. DOI: 10.1159/000216771. View

12.

Himmelmann A, Steinhauser G, Busch R, MODEST E, Noseda A, Rastetter J . Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro. Cancer Chemother Pharmacol. 1990; 26(6):437-43. DOI: 10.1007/BF02994095. View

13.

Kosano H, Takatani O . Inhibition by an alkyl-lysophospholipid of the uptake of epidermal growth factor in human breast cancer cell lines in relation to epidermal growth factor internalization. Cancer Res. 1989; 49(11):2868-70. View

14.

Storme G, Berdel W, van Blitterswijk W, Bruyneel E, De Bruyne G, Mareel M . Antiinvasive effect of racemic 1-O-octadecyl-2-O-methylglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro. Cancer Res. 1985; 45(1):351-7. View

15.

Kosano H, Takatani O . Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyl-lysophospholipid. Cancer Res. 1988; 48(21):6033-6. View

16.

Herrmann D, Neumann H . Cytotoxic ether phospholipids. Different affinities to lysophosphocholine acyltransferases in sensitive and resistant cells. J Biol Chem. 1986; 261(17):7742-7. View

17.

Berger M, Schmahl D . Modulation of chemical carcinogenesis in rats by alkyl lysophospholipids. Lipids. 1987; 22(11):935-42. DOI: 10.1007/BF02535559. View

18.

Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl H . Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). Eur J Cancer Clin Oncol. 1988; 24(9):1457-61. DOI: 10.1016/0277-5379(88)90336-7. View

19.

Okamoto S, Olson A, Berdel W, VOGLER W . Purging of acute myeloid leukemic cells by ether lipids and hyperthermia. Blood. 1988; 72(5):1777-83. View

20.

Unger C, Eibl H, Breiser A, von Heyden H, Engel J, Hilgard P . Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial. Onkologie. 1988; 11(6):295-6. DOI: 10.1159/000216563. View